Cost-utility analysis of certolizumab pegol versus alternative tumour necrosis factor inhibitors available for the treatment of moderate-to-severe active rheumatoid arthritis in Spain

Overview of attention for article published in Cost Effectiveness and Resource Allocation, June 2015

Altmetric Badge

Mentioned by

twitter: 1 X user

facebook: 1 Facebook page

Citations

dimensions_citation: 5 Dimensions

Readers on

mendeley: 59 Mendeley

Summary X Facebook Dimensions citations

So far, Altmetric has seen 1 X post from an account with 721 followers.

#HealthEconJA Cost-utility analysis of certolizumab pegol versus alternative tumour necrosis factor inhibitors ava… http://t.co/uzdVjr2QJr

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.